Hysterectomy Versus Uterine Preservation for Pelvic Organ Prolapse Surgery (HUPPS)

May 31, 2021 updated by: University of Calgary

Prospective Multi-site Cohort Study Investigating Hysterectomy Versus Uterine Preservation for Pelvic Organ Prolapse Surgery: The HUPPS Study

Pelvic organ prolapse (POP) is the descent of pelvic organs into the vagina resulting in bulge symptoms and occurs in approximately 50% of women. Almost 20% of women will elect surgical correction of this condition by age 85. Removal of the uterus (hysterectomy) with concomitant vaginal vault suspension is a longstanding practice in POP surgery to address apical (uterine) prolapse. Yet, contemporary evidence on the merits of this approach relative to preservation of the uterus through suspension is needed to better inform surgical decision-making by patients and their healthcare providers. The objective of this trial is to evaluate POP-specific health outcomes and service utilization of women electing uterine suspension compared to those electing hysterectomy and vaginal vault suspension for POP surgery up to 1-year post-surgery.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

321

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Women seeking surgical correction of POP at one of the study sites.

Description

Inclusion Criteria:

  • Have diagnosed POP of stage ≥2 using the globally recognized Pelvic Organ Prolapse-Quantification System (POP-Q)
  • Elect surgical management of POP
  • Demonstrate presence of apical prolapse on clinical exam deemed to require either a hysterectomy and concomitant vaginal vault suspension or uterine suspension to properly address their POP during surgical correction
  • Desire no further pregnancy
  • Can communicate in English
  • Are ≥18 years in age

Exclusion Criteria:

  • Prior hysterectomy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Uterine Preservation
Uterine preservation through suspension
Hysterectomy
Uterine removal and sewing the vagina upwards

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anatomic failure to correct apical POP
Time Frame: 1 year
Descent of the apex (POP-Q point C) equal to or beyond one half of the total vaginal length
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall failure to correct POP
Time Frame: 1 year
POP-Q stage ≥2 in any compartment, or re-treatment of POP with physiotherapy, pessary, or repeat surgery
1 year
Subjective failure to correct POP
Time Frame: 6 weeks; 1 year
Patient report of bulge symptoms at 6 weeks or 1 year, using one item on the PFDI-20: "Do you usually have a bulge or something falling out that you can see or feel in the vaginal area?"
6 weeks; 1 year
Length of surgery (minutes)
Time Frame: Peri-operative
Peri-operative
Estimated blood loss during surgery >500 mL
Time Frame: Peri-operative
Peri-operative
Procedural complications
Time Frame: Peri-operative
E.g., peri-operative blood transfusion, visceral injury
Peri-operative
Post-operative infection
Time Frame: Peri-operative
E.g., abscess, urinary tract infection
Peri-operative
Opioid use in-hospital
Time Frame: Peri-operative
Measured by Morphine milliequivalent (mEq)
Peri-operative
Resumption of spontaneous voiding (days)
Time Frame: Peri-operative
Peri-operative
Length of post-operative stay (days)
Time Frame: Peri-operative
Peri-operative
PROM: Total Pelvic Floor Impact Questionnaire-7 (PFIQ-7) score
Time Frame: 6 weeks; 1 year
Change from baseline
6 weeks; 1 year
PROM: Total POP Incontinence Sexual Questionnaire Revised (PISQ-IR) score
Time Frame: 6 weeks; 1 year
Change from baseline
6 weeks; 1 year
PROM: Total Pelvic Floor Distress Inventory-20 (PFDI-20) score
Time Frame: 6 weeks; 1 year
Change from baseline
6 weeks; 1 year
Presentation at the emergency department
Time Frame: 30 days (any health complaint); 1 year (pelvic floor-related complaint)
30 days (any health complaint); 1 year (pelvic floor-related complaint)
Hospital readmission
Time Frame: 30 days (any health complaint); 1 year (pelvic floor-related complaint)
30 days (any health complaint); 1 year (pelvic floor-related complaint)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2020

Primary Completion (Anticipated)

December 1, 2023

Study Completion (Anticipated)

December 1, 2024

Study Registration Dates

First Submitted

May 5, 2021

First Submitted That Met QC Criteria

May 12, 2021

First Posted (Actual)

May 18, 2021

Study Record Updates

Last Update Posted (Actual)

June 3, 2021

Last Update Submitted That Met QC Criteria

May 31, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • REB19-2134

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pelvic Organ Prolapse

Clinical Trials on Hysteropexy

3
Subscribe